Cargando...
Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia
Activating MYD88 mutations are present in 95% of Waldenström macroglobulinemia (WM) patients, and trigger NF-κB through BTK and IRAK. The BTK inhibitor ibrutinib is active in MYD88-mutated (MYD88(MUT)) WM patients, but shows lower activity in MYD88 wild-type (MYD88(WT)) disease. MYD88(WT) patients a...
Guardado en:
| Publicado en: | Blood Adv |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
American Society of Hematology
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6234368/ https://ncbi.nlm.nih.gov/pubmed/30401751 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018022962 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|